WILMINGTON, Del., May 02, 2025--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose ...

May 2 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for uncontrolled asthma ...

Breztri is an inhaled triple-combination therapy approved for chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide, including the US, EU, China, and Japan.

KALOS and LOGOS trials with 4,400 patients showed Breztri improved lung function over dual ICS/LABA therapies. No new safety concerns were found in Breztri Phase 3 asthma trials; all primary ...